Pfizer (PFE) Restructuring Costs (2009 - 2026)

Pfizer (PFE) has reported Restructuring Costs for 18 consecutive years, with $457.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Restructuring Costs rose 717.57% year-over-year to $457.0 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 58.95% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 35.92% from the prior year.
• Restructuring Costs was $457.0 million for Q2 2026 at Pfizer, up from $100.0 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $2.6 billion in Q4 2023 and troughed at -$74.0 million in Q2 2025.
• A 5-year average of $585.3 million and a median of $250.0 million in 2023 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs surged 3880.0% in 2022 and slumped 122.92% in 2023, its largest moves.
• Over 5 years, Restructuring Costs stood at $189.0 million in 2022, then surged by 1257.67% to $2.6 billion in 2023, then tumbled by 34.96% to $1.7 billion in 2024, then sank by 63.75% to $605.0 million in 2025, then decreased by 24.46% to $457.0 million in 2026.
• The last three Restructuring Costs figures came in at $457.0 million (Q2 2026), $100.0 million (Q1 2026), and $605.0 million (Q4 2025), per Business Quant data.